Revvity Inc vs Tenaris S.A. American Depositary Shares — how do they compare? Revvity Inc trades at $151.9 (market cap $17.30B), while Tenaris S.A. American Depositary Shares trades at $57.21 (market cap $29.31B). The key difference: Tenaris S.A. American Depositary Shares is the larger of the two by market cap, and Tenaris S.A. American Depositary Shares pays the higher dividend (4.07%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and Tenaris S.A. American Depositary Shares for 0 Days on average.
| RVTY | TS | |
|---|---|---|
Market Cap | $17.30B | $29.31B |
Volume | 1,387,588 | 802,043 |
Sector | Health | Energy |
52-Week High | $157.36 | $64.02 |
52-Week Low | $82.26 | $34.28 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $19.62B | $26.97B |
Dividend Yield | 0.18% | 4.07% |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →